Key factors
sym | MRNA |
exch | US |
MCap | 39.52B |
Beta | 1.601 |
EPS | -12.3 |
Div date | 0000-00-00 |
Yesterday
sym | MRNA |
exch | US |
close | 106.56 |
50 Day MA | 99.50 |
200 Day MA | 101.43 |
52 Week High | 163.24 |
52 Week Low | 62.55 |
Target Price | 129.49 |
Market Cap Mln | 39529 |
Share statistics
Shares Outstanding | 382.07M |
Shares Float | 344.71M |
Percent Institutions | 71.95 |
PercentInsiders | 9.602 |
SharesShort | 22.11M |
Short Ratio | 5.38 |
Shares Short Prior Month | 24.07M |
Short Percent | 7.689 |
Income
Revenue TTM | 6.848B |
Revenue Per Share TTM | 17.92 |
Quarterly Revenue Growth YOY | -44.6 |
Gross Profit TTM | 10.55B |
EBITDA | -3.61B |
Diluted Eps TTM | -12.3 |
Quarterly Earnings Growth YOY | -85.1 |
earning
Operating Margin TTM | 0.002 |
EPS Estimate Current Quarter | -0.9 |
EPS Estimate Current Year | -7.14 |
EPS Estimate Next Quarter | -2.62 |
EPS Estimate Next Year | -5.11 |
Earnings Share | -12.3 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Ebitda | -9.80 |
Enterprise Value Revenue | 4.765 |
Book Value /share | 36.26 |
Price Book MRQ | 2.854 |
Price Sales TTM | 5.772 |
ProfitMargin | -0.68 |
ReturnOnAssetsTTM | -0.11 |
ReturnOnEquityTTM | -0.28 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US60770K1079 |
CIK | 1682852 |
Code | MRNA |
CUSIP | 60770K107 |
Employer Id Number | 81-3467528 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-03-15 |
Home Category | Domestic |
info
Fiscal Year End | December |
ForwardPE | 32.46 |
Full Time Employees | 5600.0 |
IPODate | 2018-12-07 |
International Domestic | Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Moderna Inc |
Address | 200 Technology Square, Cambridge, MA, United States, 02139 |
Country Name | USA |
Phone | 617 714 6500 |
Web URL | https://www.modernatx.com |
Logo URL | /img/logos/US/MRNA.png |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.